NYSE:STE

STERIS - STE Stock Forecast, Price & News

$192.31

+6.57 (+3.54%)

(As of 12/1/2022 12:00 AM ET)

Add

Compare

Today's Range: $186.82
▼
$193.20
50-Day Range: $160.72
▼
$192.31
52-Week Range: $159.21
▼
$255.93

Volume: 788,554 shs
Average Volume: 535,391 shs
Market Capitalization: $19.20 billion

P/E Ratio: N/A
Dividend Yield: 1.01%
Price Target: $242.40

STERIS MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 26.0% Upside
$242.40 Price Target
Short Interest: Healthy
1.85% of Float Sold Short
Dividend Strength: Strong
Based on Four Factors
Sustainability: -2.00
Upright™ Environmental Score
News Sentiment: 0.46
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: 11.24%
From $8.45 to $9.40 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.65 out of 5 stars

Medical Sector

92nd out of 1,047 stocks

Surgical Appliances & Supplies Industry

7th out of 23 stocks

3.4

Analyst's Opinion

Consensus Rating
STERIS has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $242.40, STERIS has a forecasted upside of 26.0% from its current price of $192.31.
Amount of Analyst Coverage
STERIS has only been the subject of 2 research reports in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
1.85% of the float of STERIS has been sold short.
Short Interest Ratio / Days to Cover
STERIS has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in STERIS has recently increased by 1.10%, indicating that investor sentiment is decreasing.

3.3

Dividend Strength

Dividend Yield
STERIS pays a meaningful dividend of 1.01%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
STERIS has been increasing its dividend for 16 years.
Dividend Sustainability
Based on earnings estimates, STERIS will have a dividend payout ratio of 20.00% next year. This indicates that STERIS will be able to sustain or increase its dividend.

3.8

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
STERIS has received a 50.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Antiseptic hand rubs", "Medical endoscopes", and "Surgical masks" products. See details.
Environmental Sustainability
The Environmental Impact score for STERIS is -2.00.

1.9

News and Social Media Coverage

News Sentiment
STERIS has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for STERIS this week, compared to 4 articles on an average week.
MarketBeat Follows
Only 1 people have added STERIS to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, STERIS insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 0.95% of the stock of STERIS is held by insiders.
Percentage Held by Institutions
92.04% of the stock of STERIS is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for STERIS are expected to grow by 11.24% in the coming year, from $8.45 to $9.40 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of STERIS is -1,748.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of STERIS is -1,748.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Growth Ratio
STERIS has a PEG Ratio of 1.92. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
STERIS has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About STERIS (NYSE:STE) Stock

STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services. It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services. The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities. The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors. This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite. The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.

Receive STE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

STE Stock News Headlines

November 17, 2022 | finance.yahoo.com

Why It Might Not Make Sense To Buy STERIS plc (NYSE:STE) For Its Upcoming Dividend

November 13, 2022 | finance.yahoo.com

STERIS Second Quarter 2023 Earnings: Misses Expectations

November 9, 2022 | finance.yahoo.com

STERIS Announces Financial Results for Fiscal 2023 Second Quarter

November 2, 2022 | finance.yahoo.com

STERIS Declares $0.47 per share Dividend

October 28, 2022 | nz.finance.yahoo.com

Surgical Drapes & Gowns Market Research Report by Type, Usage Pattern, End-User, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19

October 26, 2022 | nz.finance.yahoo.com

Global Bio-Decontamination Market Report 2022: Featuring Ecolab, Fedegari Autoclavi, Steris, Tomi Environmental Solutions and JCE Biotechnology

October 26, 2022 | marketwatch.com

Washer-Disinfector-Dryers Market Size, Share 2023 Global Business Growth, Industry Revenue, Demand and Applications Market Research Report to 2028

October 26, 2022 | finance.yahoo.com

US Surface Disinfectants Market is estimated to be valued over USD 4.72 million by 2028 - Research by Exactitude Consultancy

October 25, 2022 | marketwatch.com

Surgical Lighting Systems Market Global Outlook, and Forecast 2022 To 2028.

October 25, 2022 | finance.yahoo.com

STERIS to Host a Conference Call for Fiscal 2023 Second Quarter Financial Results on November 10, 2022

October 18, 2022 | marketwatch.com

Veterinary Handheld Surgical Instrument Market 2022 Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028

October 17, 2022 | nasdaq.com

3 Fast-Growing Medical Dividend Stocks - Nasdaq

October 8, 2022 | marketwatch.com

Rotatable Snare Market Size, Share and Forecast till 2028

October 8, 2022 | marketwatch.com

Surgical Tables Market Share, Size Global Growth Prospects, Growth, Trends, Industry Analysis, Key Players and Forecast to 2028

October 8, 2022 | nasdaq.com

Is There Now An Opportunity In STERIS plc (NYSE:STE)?

October 4, 2022 | bizjournals.com

Centerline Biomedical, the Cleveland medical technology developer, hires a new CEO - The Business Journals

October 2, 2022 | fool.com

Got $3,000? Here Are 2 Stocks That Will Make You Richer - The Motley Fool

September 29, 2022 | marketwatch.com

Cleanroom Goggles Market 2022 Latest Research, Top Impacting Factors, Growth Strategies and Forecast to 2028

September 29, 2022 | marketwatch.com

Endoscope Reprocessing Market 2022 : Share and Outlook of Regulatory Scenario by 2027 with Top Countries Data

September 28, 2022 | businesswire.com

United States Patient Positioning Systems Market Trends/Analysis Report 2022-2030 Featuring Medtronic, Stryker, Hill-Rom, SchureMed, Skytron, Smith & Nephew, STERIS, Leoni, Schaerer Medical, & Mizuho - ResearchAndMarkets.com - Business Wire

September 28, 2022 | marketwatch.com

Global Ward Washer Disinfectors Market Size 2022, Share, Analysis, Development, Revenue, Future Growth, Business Prospects and Forecast to 2028

September 26, 2022 | marketwatch.com

Cordless Headlights Market Size, Types, Applications, Top Manufacturers, Growth Techniques, Future Trends and Forecast to 2028

September 23, 2022 | benzinga.com

Needham Downgrades This Medical Equipment Stock Due To Lawsuit Risk - Steris (NYSE:STE) - Benzinga

September 23, 2022 | finance.yahoo.com

Needham Downgrades This Medical Equipment Stock Due To Lawsuit Risk

September 22, 2022 | businesswire.com

Insights on the Plasma Sterilizers Global Market to 2031 - Featuring Antonio Matachana, Getinge and STERIS Among Others - ResearchAndMarkets.com - Business Wire

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive STE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for STERIS and its competitors with MarketBeat's FREE daily newsletter.

STE Company Calendar

Ex-Dividend for 9/23 Dividend: 9/06/2022
Dividend Payable: 9/23/2022
Last Earnings: 11/09/2022
Ex-Dividend for 12/16 Dividend: 11/21/2022
Today: 12/01/2022
Dividend Payable: 12/16/2022
Next Earnings (Estimated): 2/14/2023
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Surgical appliances & supplies
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NYSE:STE
CUSIP: 85915210
CIK: 1624899
Web: www.steris.com
Phone: (531) 232-2000
Fax: 440-639-4457
Employees: 16,422
Year Founded: 1987

Price Target and Rating

Average Stock Price Forecast: $242.40
High Stock Price Forecast: $275.00
Low Stock Price Forecast: $210.00
Forecasted Upside/Downside: +26.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.11)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 22.76
P/E Growth: 1.92
Net Income: $243.89 million
Net Margins: -0.17%
Pretax Margin: 1.17%
Return on Equity: 12.75%
Return on Assets: 7.23%

Debt

Debt-to-Equity Ratio: 0.49
Current Ratio: 2.16
Quick Ratio: 1.42

Sales & Book Value

Annual Sales: $4.59 billion
Price / Sales: 4.19
Cash Flow: $15.06 per share
Price / Cash Flow: 12.77
Book Value: $58.24 per share
Price / Book: 3.30

Miscellaneous

Outstanding Shares: 99,823,000
Free Float: 98,875,000
Market Cap: $19.20 billion
Optionable: Optionable
Beta: 0.80

Social Links

Key Executives

Mr. Daniel A. Carestio (Age 49)
Pres, CEO & Director
Comp: $1.63M

Mr. Michael J. Tokich (Age 53)
Sr. VP & CFO
Comp: $1.03M

Mr. John Adam Zangerle (Age 55)
Sr. VP, Gen. Counsel & Sec.
Comp: $800.03k

Mr. Walter M. Rosebrough Jr. (Age 68)
CEO Emeritus & Sr. Advisor
Comp: $1.16M

Mr. Cary L. Majors (Age 47)
Sr. VP of Americas Commercial Operations
Comp: $734.37k

Mr. Andrew Xilas (Age 57)
Sr. VP & GM of Dental
Comp: $1.44M

Ms. Karen L. Burton (Age 54)
Chief Accounting Officer, VP & Controller

Julie Winter
VP of Investor Relations & Corp. Communications

Ms. Mary Clare Fraser (Age 52)
VP & Chief HR Officer

Ms. Julia K. Madsen (Age 57)
Sr. VP of Life Sciences

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

STE Stock - Frequently Asked Questions

Should I buy or sell STERIS stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for STERIS in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" STE shares.
View STE analyst ratings or view top-rated stocks.
What is STERIS's stock price forecast for 2023?: 5 brokerages have issued 12 month price targets for STERIS's shares. Their STE share price forecasts range from $210.00 to $275.00. On average, they predict the company's stock price to reach $242.40 in the next twelve months. This suggests a possible upside of 26.4% from the stock's current price.
View analysts price targets for STE or view top-rated stocks among Wall Street analysts.
How have STE shares performed in 2022?: STERIS's stock was trading at $243.41 at the beginning of the year. Since then, STE stock has decreased by 21.2% and is now trading at $191.80.
View the best growth stocks for 2022 here.
When is STERIS's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023.
View our STE earnings forecast.
How were STERIS's earnings last quarter?: STERIS plc (NYSE:STE) released its quarterly earnings results on Wednesday, November, 9th. The medical equipment provider reported $1.99 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.98 by $0.01. The medical equipment provider had revenue of $1.20 billion for the quarter, compared to analysts' expectations of $1.22 billion. STERIS had a positive trailing twelve-month return on equity of 12.75% and a negative net margin of 0.17%. The business's revenue was up .3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.99 earnings per share.
Read the conference call transcript.
How often does STERIS pay dividends? What is the dividend yield for STERIS?: STERIS announced a quarterly dividend on Wednesday, November 2nd. Stockholders of record on Tuesday, November 22nd will be given a dividend of $0.47 per share on Friday, December 16th. This represents a $1.88 annualized dividend and a yield of 0.98%. The ex-dividend date of this dividend is Monday, November 21st.
Read our dividend analysis for STE.
Is STERIS a good dividend stock?: STERIS (NYSE:STE) pays an annual dividend of $1.88 per share and currently has a dividend yield of 1.05%.
Read our dividend analysis for STE.
What guidance has STERIS issued on next quarter's earnings?: STERIS updated its FY23 earnings guidance on Wednesday, November, 9th. The company provided earnings per share (EPS) guidance of $8.40 to $8.60 for the period, compared to the consensus EPS estimate of $8.48.

What is Walter M. Rosebrough, Jr.'s approval rating as STERIS's CEO?: 196 employees have rated STERIS Chief Executive Officer Walter M. Rosebrough, Jr. on Glassdoor.com. Walter M. Rosebrough, Jr. has an approval rating of 79% among the company's employees.
What other stocks do shareholders of STERIS own?: Based on aggregate information from My MarketBeat watchlists, some companies that other STERIS investors own include Johnson & Johnson (JNJ), Home Depot (HD), AT&T (T), Visa (V), AbbVie (ABBV), Abbott Laboratories (ABT), Pfizer (PFE), Gilead Sciences (GILD), Mastercard (MA) and Medtronic (MDT).
What is STERIS's stock symbol?: STERIS trades on the New York Stock Exchange (NYSE) under the ticker symbol "STE."
Who are STERIS's major shareholders?: STERIS's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.86%), BlackRock Inc. (8.03%), WCM Investment Management LLC (5.79%), Massachusetts Financial Services Co. MA (5.09%), State Street Corp (4.30%) and Price T Rowe Associates Inc. MD (2.26%). Insiders that own company stock include Cary L Majors, Cary L Majors, Cynthia L Feldmann, Daniel A Carestio, David B Lewis, Jacqueline B Kosecoff, John Adam Zangerle, Julia Madsen, Karen L Burton, Michael J Tokich, Mohsen Sohi, Renato Tamaro, Richard C Breeden, Richard Martin Steeves and Walter M Rosebrough Jr.
View institutional ownership trends.
How do I buy shares of STERIS?: Shares of STE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is STERIS's stock price today?: One share of STE stock can currently be purchased for approximately $191.80.
How much money does STERIS make?: STERIS (NYSE:STE) has a market capitalization of $19.15 billion and generates $4.59 billion in revenue each year. The medical equipment provider earns $243.89 million in net income (profit) each year or ($0.11) on an earnings per share basis.
How many employees does STERIS have?: The company employs 16,422 workers across the globe.
How can I contact STERIS?: STERIS's mailing address is 70 Sir John Rogerson`s Quay, Dublin L2, D02 R296. The official website for the company is www.steris.com. The medical equipment provider can be reached via phone at (531) 232-2000, via email at julie_winter@steris.com, or via fax at 440-639-4457.

This page (NYSE:STE) was last updated on 12/2/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial